Eliminating drug target interference with specific antibody or its F(ab')2 fragment in the bridging immunogenicity assay
Background: DB-1003 is a humanized anti-IgE monoclonal antibody with higher affinity than omalizumab. In the affinity capture elution (ACE)-based bridging electrochemiluminescent immunoassay (ECLIA) for antibodies to DB-1003, monkey serum IgE caused false-positive results. Materials & methods: The target-specific antibody or its F(ab')2 fragment was used to mitigate drug target interference in an ACE-based bridging ECLIA for the detection of anti-DB-1003 antibodies. Results: The sensitivity of the developed assay was at least 100 ng/ml. When the anti-drug antibody concentration was 250 ng/ml, the assay tolerated at least 20.0 μg/ml of the monkey IgE. Conclusion: Incorporating the target-specific antibody or its F(ab')2 fragment can overcome the interference from monkey serum IgE in ACE-based bridging ECLIA for anti-DB-1003 antibody detection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Bioanalysis - 16(2024), 7 vom: 26. März, Seite 135-148 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Deng, Xiaojie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
37341-29-0 |
|---|
| Anmerkungen: |
Date Completed 26.03.2024 Date Revised 26.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/bio-2023-0191 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368759113 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368759113 | ||
| 003 | DE-627 | ||
| 005 | 20240326235511.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240222s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/bio-2023-0191 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1348.xml |
| 035 | |a (DE-627)NLM368759113 | ||
| 035 | |a (NLM)38385901 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Deng, Xiaojie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Eliminating drug target interference with specific antibody or its F(ab')2 fragment in the bridging immunogenicity assay |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.03.2024 | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: DB-1003 is a humanized anti-IgE monoclonal antibody with higher affinity than omalizumab. In the affinity capture elution (ACE)-based bridging electrochemiluminescent immunoassay (ECLIA) for antibodies to DB-1003, monkey serum IgE caused false-positive results. Materials & methods: The target-specific antibody or its F(ab')2 fragment was used to mitigate drug target interference in an ACE-based bridging ECLIA for the detection of anti-DB-1003 antibodies. Results: The sensitivity of the developed assay was at least 100 ng/ml. When the anti-drug antibody concentration was 250 ng/ml, the assay tolerated at least 20.0 μg/ml of the monkey IgE. Conclusion: Incorporating the target-specific antibody or its F(ab')2 fragment can overcome the interference from monkey serum IgE in ACE-based bridging ECLIA for anti-DB-1003 antibody detection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a IgE | |
| 650 | 4 | |a anti-drug antibody | |
| 650 | 4 | |a immunogenicity | |
| 650 | 4 | |a mitigation | |
| 650 | 4 | |a target interference | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Immunoglobulin E |2 NLM | |
| 650 | 7 | |a 37341-29-0 |2 NLM | |
| 650 | 7 | |a Immunoglobulin Fab Fragments |2 NLM | |
| 700 | 1 | |a Hou, Yingying |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Wenyi |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Hongzhou |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Ruowen |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Tingting |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yongzhen |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Junjiu |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Heng |e verfasserin |4 aut | |
| 700 | 1 | |a Gong, Likun |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Qiuping |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioanalysis |d 2009 |g 16(2024), 7 vom: 26. März, Seite 135-148 |w (DE-627)NLM196969840 |x 1757-6199 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2024 |g number:7 |g day:26 |g month:03 |g pages:135-148 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/bio-2023-0191 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2024 |e 7 |b 26 |c 03 |h 135-148 | ||